Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 90%. A quarter ago, it was expected that this drug developer would post a loss of $0.21 per share when it actually produced a loss of $0.14, delivering a surprise of 33.33%.Over the last four quarters, the company has ...